Ogechi Amachukwu, NP
Family · Houston, TXNPI 1679013429
Payments from drug & device makers
Across 100 payments — averaging $94.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intrinsic Therapeutics$7K
- AbbVie$413
- Merz Pharmaceuticals, LLC$298
- Lilly USA, LLC$188
- Globus Medical$150
- Takeda Pharmaceuticals U.S.A., Inc.$98
- plus $830 from 21 others
What the payments were for
- Consulting fees$5,62559%
- Travel & lodging$1,05411%
- Food & beverage$2,77729%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intrinsic Therapeutics | 18 | $7,478 |
| AbbVie | 22 | $413 |
| Merz Pharmaceuticals, LLC | 12 | $298 |
| Lilly USA, LLC | 9 | $188 |
| Globus Medical | 1 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $98 |
| SK Life Science, Inc. | 3 | $81 |
| Acadia Pharmaceuticals Inc | 3 | $72 |
| Si-bone, Inc. | 2 | $69 |
| UCB, Inc. | 3 | $68 |
| Ipsen Biopharmaceuticals, Inc | 2 | $66 |
| Bioventus LLC | 2 | $65 |
| Averitas Pharma Inc. | 3 | $59 |
| Eisai Inc. | 2 | $43 |
| Lundbeck LLC | 2 | $39 |
| Boston Scientific | 1 | $34 |
| AstraZeneca | 1 | $28 |
| Medtronic | 1 | $28 |
| Johnson & Johnson | 1 | $27 |
| Nanohive Medical LLC | 1 | $26 |
| Grifols USA, LLC | 1 | $25 |
| SPR Therapeutics, Inc | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Orphalan Inc | 1 | $19 |
| Insightec,inc | 1 | $14 |
| Curonix LLC | 1 | $13 |
| Stimwave Technologies Incorporated | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,456 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 91 | $1,007 |
| Tizanidine Hcl | 100 | $965 |
| Methylprednisolone | 83 | $522 |
| Pregabalin | 13 | $442 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 25 | $308 |
| Methocarbamol | 37 | $238 |
| Levetiracetam | 13 | $187 |
| Tramadol Hcl | 49 | $161 |
| Ibuprofen | 14 | $83 |
| Meloxicam | 18 | $77 |
| Diazepam | 13 | $6 |
Paid to pharmacies, not to this prescriber.
Other family in Houston
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Margaret WhiteHouston$85K
- Cheryl HaseebHouston$42K
- David WeirDallas$959K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.